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SHORT REPORT Open Access
Co-infection with HPV types from the same
species provides natural cross-protection from
progression to cervical cancer
Rafal S Sobota1,2,6*, Doreen Ramogola-Masire3,4,5, Scott M Williams2 and Nicola M Zetola3,4,5*
Abstract
Background: The worldwide administration of bivalent and quadrivalent HPV vaccines has resulted in cross-protection
against non-vaccine HPV types. Infection with multiple HPV types may offer similar cross-protection in the natural
setting. We hypothesized that infections with two or more HPV types from the same species, and independently,
infections with two or more HPV types from different species, associate with protection from high-grade lesions.
Findings: We recruited a cohort of 94 HIV, HPV-positive women from Botswana, with Grade 2 or higher cervical
intraepithelial neoplasia. Infections with 2 or more HPV types from a single species associated with reduced lesion
severity in univariate analysis (OR = 0.41, 95% CI 0.18-0.97, p = 0.042), when adjusted for the presence of HPV 16 or 18
types (OR = 0.41, 95% CI 0.17-1.00, p = 0.049), or all high-risk HPV type infections (OR = 0.38, 95% CI 0.16-0.90, p = 0.028).
Infections with 2 or more HPV types from different species did not associate (OR = 0.68, 95% CI 0.25-1.81, p = 0.435).
Conclusions: Our findings show that co-infections with genetically similar HPV types reduce the likelihood of progression
to high-grade lesions in HIV positive women, an effect not observed in co-infections with taxonomically different HPV
types. This observation is possibly caused by an immune cross-protection through a similar mechanism to that observed
after HPV vaccination.
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Background
Cervical cancer is the third most common cancer in
women worldwide and the number one cause of cancer-
related mortality in Sub-Saharan Africa [1]. Infection
with an oncogenic human papillomavirus (HPV) type is
necessary, but not sufficient, for progression to cervical
cancer [2]. Most HPV types do not cause cancer, and
position on the viral phylogeny affects disease risk [3,4].
HPV phylogeny is based on genetic distance between
isolates, with the genus serving as the broadest taxon.
Within a genus, similar viruses are classified into
species, and viruses within a species are subdivided into
types [5,6]. Only the alpha genus of HPV is associated
with cervical cancer [7]. The carcinogenic HPV types fall
into 5 species, α5, α6, α7, α9 and α11 [3] and are termed
high-risk species. Two HPV types, 16 and 18, are re-
sponsible for approximately 70% of cervical cancer cases
worldwide; with the majority of the remainder ascribed
to 11 other types [8].
Vaccination against HPV was a major advance in cer-
vical cancer prevention, offering protection against a few
disease causing types. Currently, 2 prophylactic vaccines
are approved for human use. The tetravalent vaccine
covers four HPV types, offering protection against cer-
vical cancer (types 16 and 18) as well as genital warts
(types 6 and 11). The bivalent vaccine covers types 16
and 18, targeting only cervical cancer [5,6,9]. Under-
standing the effects of HPV co-infections is essential in
determining the long term effects of the vaccines. Avail-
ability of such results can better inform the projections
on the effect of broad vaccine implementation, and the
subsequent prevalence of cervical cancer. Available data
suggest that both vaccines have a variable level of cross-
protection against types closely related HPV types [10].
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It is hypothesized that this protection can be attributed
to the genetic similarity between the vaccine types and
those against which cross-protection is afforded, as the
types for which cross-protection was observed are in the
same species as HPV 16 and 18.
In this study we determined whether taxonomic rela-
tionships of co-infecting HPV types associated with pro-
gression to advanced cervical lesions (CIN3+). We tested
two independent hypotheses: 1) infections with two or
more HPV types from the same species associate with
progression to high-grade lesions; or 2) infections with
two or more HPV types from different species associate
with progression to high-grade lesions.
Findings
We recruited HIV-positive women living in Botswana
who were diagnosed with a Grade 2 or higher cervical
intraepithelial neoplasia (CIN2 or above) on colposcopy.
All patients provided informed consent.
Specimen collection and processing have been previ-
ously described [11]. Briefly, Pap smear swabs were lysed
in 500 μL of lysis buffer (Roche MagNA Pure LC DNA
Isolation Kit) for 30 minutes at room temperature. DNA
was extracted, amplified and analyzed following the
manufacturer’s specifications (Roche Linear Array® HPV
Genotyping test). This method can detect 13 high-risk
HPV genotypes (genotypes 16, 18, 31, 33, 35, 39, 45, 51,
52, 56, 58, 59, and 68) and 24 low-risk HPV genotypes
(genotypes 6, 11, 26, 40, 42, 53, 54, 55, 61, 62, 64, 66, 67,
69, 70, 71, 72, 73, 81, 82, 83, 84, IS39, and CP6108).
HPV types were assigned to species using conventional
taxonomic criteria [5,6]. Briefly, using the L1 ORF of
papillomaviruses, viruses with <60% sequence homology
in this region are considered to be in a different genus.
Sequence homology between 60 and 70% constitutes dif-
ferent species, while different HPV types within a spe-
cies have between 70 and 89% nucleotide identity [5,6].
Only HPV types in the alpha-papillomavirus genus were
considered in our study.
Univariate logistic regression was used to determine
association between CIN3 lesions (as opposed to CIN2)
and three categories of HPV co-infection, separately.
The HPV co-infection categories were: 1) two or more
HPV types from two or more species, 2) two or more
HPV types from a single species, 3) two or more HPV
types from a single high-risk species (α5, α6, α7, α9 or
α11 [3]).
We also tested the association between CIN3 lesions
and variables previously associated with CIN progres-
sion; namely: baseline CD4 count, patient age at the time
of screening, patient age at the time of first intercourse,
and lifetime number of sexual partners [12]. Univariate
logistic regression was performed between presence of
CIN3 and each variable. Univariate analyses were used
to separately model the three categories of patient HPV
as the dependent variable and patient CD4 counts either
at presentation or the last available CD4 value as the
independent variables.
Multivariate logistic regression models of CIN3 were
tested, separately using the 3 HPV co-infection categor-
ies above, along with other variables statistically signifi-
cant in univariate analyses. Presence of HPV 16 or 18, or
the presence of a high-risk HPV of any type was also
included in the model.
Study population
94 women with CIN2, CIN3, and squamous cell carcin-
oma made up the final study population. 41 of the pa-
tients had CIN2, 52 had CIN3, and one had squamous
cell carcinoma (SCC). The squamous cell carcinoma pa-
tient was categorized as CIN3 in the logistic regression
analyses (ordinal analyses with a separate SCC category
yielded comparable results, Additional file 1: Table S1).
The mean age of study participants was 36.78 and the
median number of HPV type co-infections per patient
was 3 (Table 1).
The classification of HPV types into species is pre-
sented in Additional file 1: Table S2 [13]. 79 patients
were infected with multiple HPV types. 72 patients had
two or more HPV types from different species, 53 pa-
tients had two or more HPV types from a single species,
and 40 patients had two or more HPV types from a
single high-risk species. We found co-infections with
only single HPV types of multiple species in 26 patients.
Seven patients were infected with multiple HPV types
from one species exclusively, all of which were high-risk
species. 46 patients had infections with both HPV types
in multiple species and multiple HPV types in the same
species. 90 patients were infected with a high-risk HPV
type, while 50 patients had an infection with either HPV
16 or 18.
Univariate analyses
Infection with two or more HPV types from a single
species protected against progression to higher risk
lesions (OR = 0.41, 95% CI 0.18-0.97, p = 0.042; Table 2).
Infection with two or more HPV from a single high-risk
Table 1 Summary statistics of study population
Variable Mean (st dev) Median (IQR)
Age 36.78 (5.90) 36 (33-39)
HPV infections per person 3.93 (2.62) 3 (2-5)
Age at first intercourse* 18.13 (2.32) 18 (16-20)
Number of lifetime sexual partners* 5.86 (5.26) 4 (3-6)
CD4 count during first visit** 254.85 (207.29) 200 (109-365)
CD4 count during last visit 452.43 (208.12) 426 (285-578)
Data available for 63 patients* and for 61 patients**.
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species was also protective (OR = 0.37, 95% CI 0.16-0.86,
p = 0.021). Infection with two or more HPV types from
different species did not associate with progression (OR
= 0.68, 95% CI 0.25-1.81, p = 0.435).
Univariate regression of CIN3 with a patient’s CD4
count at first presentation, last available CD4 count, pa-
tient’s age, number of lifetime sexual partners, and most
of the individual high-risk HPV types were not statis-
tically significant (Table 2, Additional file 1: Table S3).
Patients with HPV types 39 were always diagnosed with
CIN3, and those with HPV 26, 40, or 73 always had
CIN2 (Additional file 1: Table S3). HPV 51 also associ-
ated with CIN3 (OR = 0.16, 95% CI 0.03-0.81, p = 0.027)
(Additional file 1: Table S3). In our sample, infection
with either HPV 16 or 18 was not associated with pro-
gression to CIN3 (p = 0.62). Initial and last available
CD4 counts were not associated with the presence of
any of the HPV co-infection categories (Table 2).
Multivariate analyses
In multivariate analysis, the association of CIN3 with
two or more HPV type infections from multiple species
was not significant when adjusting for high-risk HPV
type infections (OR = 0.61, 95% CI 0.22-1.63, p = 0.322;
Table 2). Association of CIN3 with two or more HPV
type infections from a single species was significant
when adjusting for high-risk HPV type infections (single
species co-infection OR = 0.38, 95% CI 0.16-0.90, p =
0.028; Table 2). Infections with two or more HPV types
from a single high-risk species were significant in multi-
variate analyses adjusted for all high-risk HPV (OR =
0.42, 95% CI 0.18-0.97, p = 0.044; Table 2).
Discussion
Our results indicate that the presence of infections with
two or more HPV types from the same species protects
from progression to high-grade CIN. While our data did
not longitudinally ascertain the sequence of infection
events, it is likely that some portion of our patients were
infected with a low-risk HPV type prior to the acquisition
of a high-risk type from the same species. This sequence
of events could boost the immune system against the
high-risk types and provide cross-protection via a mech-
anism similar to that afforded for HPV 31 and 45 infec-
tions when using vaccines [14].
Table 2 Univariate and multivariate logistic regression results modeling CIN3 presence/absence or HPV co-infections
Outcome Covariate(s) Odds ratio 95% CI p value
Presence of CIN3 Multiple types single species 0.4145 0.177-0.970 0.042
Presence of CIN3 Multiple types different species 0.6753 0.252-1.808 0.435
Presence of CIN3 Multiple types single high-risk species 0.3696 0.159-0860 0.021
Presence of CIN3 HPV 16 or 18 0.8127 0.358-1.843 0.620
Presence of CIN3 Age 1.0204 0.951-1.095 0.576
Presence of CIN3 Sexual Partners* 0.9997 0.909-1.099 0.994
Presence of CIN3 Age at First Sex* 1.0722 0.861-1.336 0.534
Presence of CIN3 CD4 count at presentationϮ 1.0014 0.998-1.004 0.297
Presence of CIN3 Last available CD4 count 1.0003 0.998-1.002 0.746
Presence of CIN3 Multiple types from single species; high-risk HPVǂ 0.3783 0.159-0.899 0.028
Presence of CIN3 Multiple types from single species; HPV 16 or 18 0.4138 0.172-0.996 0.049
Presence of CIN3 Multiple types from different species; high-risk HPVǂ 0.6061 0.225-1.632 0.322
Presence of CIN3 Multiple types from different species; HPV 16 or 18 0.6980 0.256-1.900 0.482
Presence of CIN3 Multiple types from single high-risk species; high-risk HPVǂ 0.4158 0.177-0.975 0.044
Presence of CIN3 Multiple types from single high-risk species; HPV 16 or 18 0.3661 0.155-0.847 0.024
2+ HPV infections CD4 count at presentation 0.9978 0.995-1.001 0.168
2+ HPV infections Last available CD4 count 0.9980 0.995-1.001 0.130
Multiple types single species CD4 count at presentation 1.0001 0.998-1.002 0.963
Multiple types single species Last available CD4 count 0.9995 0.998-1.001 0.618
Multiple types single high-risk species CD4 count at presentation 1.0006 0.998-1.003 0.623
Multiple types single high-risk species Last available CD4 count 1.0008 0.999-1.003 0.413
Multiple types different species CD4 count at presentation 0.9980 0.995-1.001 0.187
Multiple types different species Last available CD4 count 0.9981 0.996-1.000 0.106
Data available for 63 patients* and for 61 patientsϮ. 90 patients had high risk HPV typesǂ.
Sobota et al. Infectious Agents and Cancer 2014, 9:26 Page 3 of 5
http://www.infectagentscancer.com/content/9/1/26
Cross-reactive immune response based on taxonomic
placement has been previously considered among HPV
vaccines [15]. Immune responses to natural infection
have been shown to be weaker than those elicited by
the vaccines [14]. However, the persistence of HPV infec-
tions coupled with the immunodominant nature of the re-
sponse, generating antibodies to only a subset of antigens,
makes natural cross-protection an important factor to
consider [16]. Cross-reactivity could offer a degree of pro-
tection capable of preventing or delaying carcinogenesis to
only a subset of similar type infections (same species) but
not strong enough to clear the infection. This mechanism
could account for the effects observed in our study. This
conclusion is further supported by the result that co-
infections with HPV types from different species did not
associate with protection for progressing to CIN3, while
univariate analyses of same species infections in only the
five high-risk species provided stronger associations and
effect sizes than same species infections in general (Table 2,
Additional file 1: Table S1). Hence sequence similarity
among co-infections increases protection.
HIV and resultant low CD4 counts have been previously
associated with increased risk of single and multiple HPV
infections [17]. However, in our study, HIV-associated im-
munosuppression was not predictive of multiple HPV
infections (Table 2). We observed no effect of CD4 counts
on the likelihood of acquisition of co-infections with mul-
tiple HPV species, regardless of category (Table 2). This
leads us to suggest that our findings are applicable beyond
the niche of HIV + patients.
Our data, observed in an unvaccinated, natural setting,
indicate that protection from any high-risk species type is
likely to confer some degree of protection against all types
in that species, supporting the argument that vaccines
would do better if all high-risk species were covered.
Therefore, widespread use of HPV vaccines can indirectly
affect the prevalence of some non-vaccine types. Since the
bivalent vaccine covers species α7 and α9, and the quadri-
valent adds protection to α10, the burden of HPV carcino-
genesis in a fully vaccinated population might shift to the
high-risk species that are not currently covered by either
vaccine; namely α5, α6, and α11. Adding virus-like par-
ticles from at least one HPV type in each of these spe-
cies should therefore be a priority for future vaccine
development.
This study was reviewed and approved by the Institu-
tional Review Boards of the University of Pennsylvania
and the Botswana Ministry of Health.
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Additional file 1: Table S1. Univariate and multivariate ordinal
regression modeling lesion severity, CIN2 = 0, CIN3 = 1, and SCC = 2, with
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HPV types found in this study into species of the alpha-papillomavirus
genus. Table S3. Univariate logistic regression results of progression to
CIN 3 versus individual HPV types.
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